Bone-Related Diseases: From Molecular Mechanisms to Therapy Development—2nd Edition

Topic Information

Dear Colleagues,

The prevalence and incidence of bone-related diseases (fractures, osteoarthritis, osteoporosis, bone tumors, etc.) are increasing with the current developments in society, especially in the aging population. These diseases often result in pain and disability and incapacitate people in their daily life, which imposes a considerable global socioeconomic burden. Therefore, it is imperative to explore the biomarkers and molecular mechanisms for early diagnosis and targeted treatment of bone-related diseases. With the rise in systematic biology and bioinformatics, more analytical techniques, including single-cell sequencing (scSeq), cytometry by time-of-flight (CyTOF), and bulk RNA-Seq, have been applied to achieve a deeper understanding of the mechanisms of these diseases, such as their genomics, proteomics, metabolomics, and transcriptomics. Particularly, molecular mechanisms of bone-related diseases could be identified from the analysis of genes, proteins, metabolites, etc. In this Topic, we welcome original research or review articles relating to new insights into pathogenesis, potential biomarkers, and recent advances in the study of bone-related diseases. The submission of original articles, reviews, mini-reviews, and commentaries is welcomed. Topics of interest include but are not limited to the following:

• Mechanism of action research, including molecular and cellular mechanisms and key signaling pathways in bone-related diseases.
• Novel therapeutic strategies in the treatment of bone-related diseases.
• Biomarker studies in bone tumors and other bone-related diseases.
• Drug development, including PD, PK, toxicity, and efficacy evaluation, for osteoarthritis, osteoporosis, and other bone-related diseases.
• Clinical trials, including on osteoarthritis, osteoporosis, and bone tumors.

Dr. Xin Dong
Dr. Xiao Wang
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Biomedicines biomedicines	3.9	6.8	2013	21 Days	CHF 2600	Submit
Biomolecules biomolecules	4.8	9.2	2011	17.9 Days	CHF 2700	Submit
Cells cells	5.2	10.5	2012	15.5 Days	CHF 2700	Submit
International Journal of Molecular Sciences ijms	4.9	9.0	2000	17.8 Days	CHF 2900	Submit
Journal of Clinical Medicine jcm	2.9	5.2	2012	18.5 Days	CHF 2600	Submit
Osteology osteology	-	-	2021	25 Days	CHF 1000	Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Related Topic

Published Papers (2 papers)

Order results

Content type Publication Date

Result details

Normal Extended Compact

Journals

All Biomolecules IJMS JCM Biomedicines Osteology Cells

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

Error

Oops... you haven't selected anything for export.

Ok

clear

20 pages, 345 KB  

Open AccessReview

Drug-Induced Osteoporosis

by Rudolf Wolfgang Gasser, Roland Kocijan, Afrodite Zendeli and Heinrich Resch

J. Clin. Med. 2026, 15(3), 993; https://doi.org/10.3390/jcm15030993 - 26 Jan 2026

Viewed by 912

Abstract

The administration of various medications can induce bone loss as an adverse effect and may result in drug-induced osteoporosis, an important and clinically relevant form of secondary osteoporosis associated with an increased fracture risk. This review summarizes the skeletal effects of selected commonly [...] Read more.

The administration of various medications can induce bone loss as an adverse effect and may result in drug-induced osteoporosis, an important and clinically relevant form of secondary osteoporosis associated with an increased fracture risk. This review summarizes the skeletal effects of selected commonly used drugs with respect to bone metabolism, bone mineral density, and fracture outcomes. Medications may exert direct effects on osteoblasts and/or osteoclasts, leading to impaired bone remodeling and reduced bone mass. Alternatively, indirect mechanisms may contribute to skeletal damage, including disturbances in calcium and vitamin D metabolism with subsequent secondary hyperparathyroidism, as well as therapy-induced hypogonadism. Drug classes frequently associated with drug-induced osteoporosis during long-term use include glucocorticoids, aromatase inhibitors, androgen-deprivation therapy, thyroxine, proton pump inhibitors, anticoagulants (heparin and vitamin K antagonists), antidepressants, neuroleptics, and thiazolidinediones. Importantly, this overview represents a selection of relevant agents and does not aim to provide an exhaustive list. When prescribing potentially bone-damaging medications over extended periods, particularly in older individuals, bone health should be proactively considered. Evaluation should include laboratory assessment, fracture risk estimation (e.g., FRAX^®), and bone mineral density measurement when appropriate. Adequate calcium and vitamin D intake should be ensured, and guideline-based osteoporosis therapy initiated when indicated. Full article

(This article belongs to the Topic Bone-Related Diseases: From Molecular Mechanisms to Therapy Development—2nd Edition)

attachment

Supplementary material:
Supplementary File 1 (ZIP, 183 KB)

17 pages, 1174 KB  

Open AccessBrief Report

Novel SNP Combination for Predictive Osteoporotic Diagnosis

by Julia V. Sopova, Olga A. Krasnova, Polina I. Semenova, Julia D. Kryukova, Giomar V. Vasileva, Anna S. Zhuk, Olga M. Lesnyak, Vitaliy V. Karelkin and Irina E. Neganova

Int. J. Mol. Sci. 2025, 26(22), 11117; https://doi.org/10.3390/ijms262211117 - 17 Nov 2025

Viewed by 866

Abstract

Osteoporosis is a multifactorial disease, the pathogenesis of which is caused by a complex interaction of genetic, hormonal, and metabolic factors. The challenges of early diagnosis highlight the need to identify genetic predictors to prevent bone mineral density (BMD) loss. Given the critical [...] Read more.

Osteoporosis is a multifactorial disease, the pathogenesis of which is caused by a complex interaction of genetic, hormonal, and metabolic factors. The challenges of early diagnosis highlight the need to identify genetic predictors to prevent bone mineral density (BMD) loss. Given the critical role of G-protein-coupled receptors (GPCRs) in bone development and remodeling, we investigated osteoporosis-associated single-nucleotide polymorphisms (SNPs) within GPCR genes using next-generation sequencing of patient cohorts. Subsequent screening via Sanger sequencing identified three SNPs for further analysis: rs1991517 in the thyroid-stimulating hormone receptor gene (TSHR), rs6166 in the follicle-stimulating hormone receptor gene (FSHR), and rs1042713 in the β2-adrenergic receptor gene (ADRB2). Our results reveal a significant association between osteoporosis and a specific homozygous genotype combination (TSHR rs1991517 CC, FSHR rs6166 AA, and ADRB2 rs1042713 AA). The functional impairment in osteodifferentiation was further validated in patient-derived cell lines harboring this triple-SNP combination. Thus, this study is the first to identify a specific combination of GPCR gene polymorphisms that may serve as a predictive biomarker for osteoporosis in early genetic screening. Full article

(This article belongs to the Topic Bone-Related Diseases: From Molecular Mechanisms to Therapy Development—2nd Edition)

►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

 

Error

Oops... you haven't selected anything for export.

Ok

clear

Displaying articles 1-2